血漿タンパク質治療薬市場：製品、用途別-2024-2030年の世界予測

血漿タンパク質治療薬市場規模は2023年に325億5,000万米ドルと推計され、2024年には361億9,000万米ドルに達し、CAGR 11.37％で2030年には691億8,000万米ドルに達すると予測されています。

血漿タンパク質治療薬は、人間の健康に必要な様々な機能を担う必須タンパク質を含む血液の液体成分であるヒト血漿から得られる医薬品で構成されています。これらの治療薬には、特定の血漿タンパク質の欠如や機能不全に起因する様々な病状に対処するために調整された、高度に専門化された治療法の数々が含まれます。血漿タンパク質治療薬の市場開拓には、臨床使用のためのこれらのタンパク質の開発、生産、流通が含まれます。自己免疫疾患や神経疾患の有病率の増加と、患者の生涯を通じて定期的な輸液や注射の必要性の増加が、血漿タンパク質治療薬市場の成長に寄与しています。また、血漿蛋白質療法へのアクセスが急増し、患者にとって手頃な価格であることも市場開拓の原動力となっています。血漿タンパク質治療薬の副作用と血漿タンパク質の取り扱いに関する厳しい規制が市場の成長を制限しています。血漿タンパク質に関連する研究開発活動の増加は、血漿タンパク質治療薬市場の潜在的成長機会を示しています。効率的なタンパク質血漿抽出/製造プロセスの開拓が市場の成長をもたらすと期待されています。

製品HAEに伴う腫脹発作の制御と予防のためのC1-エステラーゼ阻害剤の使用増加

肝臓で合成されるタンパク質であるアルブミンは、血圧を維持し、ホルモン、酵素、薬剤を輸送する役割を担っています。治療例では、アルブミンはショックや熱傷の際の容積増加剤として、また肝不全、ネフローゼ症候群、胃腸の蛋白喪失による低アルブミン血症の治療にしばしば使用されます。C1-エステラーゼ阻害薬は、身体の免疫反応の一部である補体系を調節するタンパク質です。主に遺伝性血管性浮腫（HAE）の治療に使用されます。HAEは身体の様々な部位に腫れを引き起こす稀な遺伝性疾患です。凝固因子は血液凝固プロセスに不可欠なタンパク質です。治療用凝固因子は、血液凝固を障害する遺伝性疾患である血友病AおよびBの患者さんの出血を予防し、コントロールします。治療には、欠損または欠損した凝固因子を補充することが必要であり、出血エピソードを予防するために予防的に投与したり、急性出血を管理するために必要に応じて投与したりします。高免疫グロブリンは、特定の病原体や毒素を標的とする抗体を高濃度に含む血漿由来の免疫グロブリンです。免疫不全患者におけるB型肝炎、狂犬病、破傷風、ある種の感染症などの疾患の予防や治療に使用されます。免疫グロブリン（Ig）は抗体としても知られ、自己免疫疾患や炎症性疾患、原発性免疫不全症や二次性免疫不全症、特定の感染症などの幅広い治療に使用されます。免疫グロブリン静注（IVIg）と皮下免疫グロブリン静注（SCIg）の2つが主な製剤形態であり、その選択は患者の嗜好、忍容性、静脈への到達性に大きく依存します。血漿蛋白製剤の選択は、特定の臨床ニーズによって決定されます。アルブミンと凝固因子は、それぞれ重要な血漿量と凝固機能を提供し、後者については外傷や手術、出血コントロールのような緊急性の高い使用事例が多いです。C1-エステラーゼ阻害剤と高免疫グロブリンは、遺伝性疾患や感染症に焦点を当てた、より的を絞った介入を提供します。免疫グロブリンは、自己免疫疾患や免疫不全に関連する様々な疾患の治療薬として、最も幅広い用途に使用されています。遺伝子治療や既存の治療法の適応拡大といった最近の進歩により、医療ニーズに積極的に対応する少数の主要企業が製造業界を支配しています。

用途がんおよび自己免疫疾患の流行による二次性免疫不全症における血漿タンパク質治療薬の用途拡大

遺伝性血管性浮腫は、身体の様々な部位に突然、重篤かつ予測不可能な腫脹を示す稀な遺伝性疾患です。HAEの治療には、C1エステラーゼ阻害剤（C1-INH）濃縮製剤が使用され、最近では、オンデマンド治療および予防として遺伝子組換えC1-INH療法とカリクレイン阻害剤が使用されています。HAE発作が生命を脅かすものであることから、これらの治療に対するニーズは高いです。特発性血小板減少性紫斑病は自己免疫疾患であり、血小板数が減少し、あざができやすく、出血しやすくなります。ITPの治療には、血小板数を速やかに上昇させることができる免疫グロブリン静注（IVIG）が一般的に用いられます。原発性免疫不全症（PID）は、体の免疫系の一部が欠損していたり、機能が不適切であったりする300以上の疾患群です。通常、患者は生涯にわたる治療が必要となり、多くの場合、免疫グロブリン（Ig）の補充が必要となります。二次性免疫不全症（SID）は、感染症、化学療法、他の疾患などの外部要因によって免疫系が障害された場合に生じる。これら4つの応用分野における治療ニーズは大きく異なり、その需要は各疾患の激しさと慢性的な性質の両方によって形成されます。HAEとITPが一般的に迅速な対応治療を必要とするのに対し、PIDとSIDは長期的な管理戦略を必要とします。

地域別の洞察

南北アメリカの血漿タンパク質治療薬市場は、先進的なヘルスケアインフラ、高い患者意識レベル、主要な業界プレイヤーの存在に牽引され、米国が主要な世界市場のひとつとなっています。FDA（米国食品医薬品局）による規制環境は、厳格な品質と安全基準を保証しています。南米では、ブラジルとアルゼンチンが、ヘルスケア支出の増加と血漿由来療法に対する意識の高まりから、血漿タンパク質治療薬の主要市場として台頭してきています。アジア太平洋（APAC）地域は、ヘルスケアに対する意識の高まり、可処分所得の増加、高齢化の進展により、血漿タンパク質治療薬市場に成長機会をもたらしています。中国と日本はこの地域の重要な市場であり、中国は血漿採取と分画機能に多額の投資を行っています。欧州には確立されたヘルスケアシステム、質の高い基準、有利な償還政策があります。免疫グロブリンのニーズは依然として旺盛で、欧州諸国は血漿製品の重要な輸出国です。湾岸協力会議（GCC）諸国では、経済的繁栄とヘルスケア支出の増加により、血漿タンパク質治療薬に対するニーズが高まっています。逆にアフリカは、血漿由来の医薬品への関心は高まっているもの、ヘルスケアインフラや治療へのアクセスにおいてかなりのハードルに直面しています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは血漿タンパク質治療薬市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、血漿タンパク質治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.血漿タンパク質治療薬市場の市場規模および予測は？

2.血漿タンパク質治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.血漿タンパク質治療薬市場の技術動向と規制枠組みは？

4.血漿タンパク質治療薬市場における主要ベンダーの市場シェアは？

5.血漿タンパク質治療薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 自己免疫疾患および神経疾患の罹患率の増加
    • 患者の生涯にわたる定期的な点滴や注射の必要性
    • 患者にとって血漿タンパク質療法へのアクセスと手頃な価格の急増
  • 抑制要因
    • 血漿タンパク質治療薬の悪影響
  • 機会
    • 血漿タンパク質に関する研究開発活動の増加
    • 効率的なタンパク質血漿抽出・製造プロセスの開発
  • 課題
    • 血漿タンパク質の取り扱いに関する厳格な規制
• 市場セグメンテーション分析
  • 製品：HAEに伴う腫れの発作を抑制および予防するためのC1エステラーゼ阻害剤の使用増加
  • 応用：がんや自己免疫疾患の蔓延による二次免疫不全における血漿タンパク質治療薬の応用が拡大
• 市場動向分析
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析
• 顧客のカスタマイズ

第6章 血漿タンパク質治療薬市場：製品別

• アルブミン
• C1エステラーゼ阻害剤
• 凝固因子
• 高度免疫グロブリン
• 免疫グロブリン

第7章 血漿タンパク質治療薬市場：用途別

• 遺伝性血管性浮腫
• 特発性血小板減少性紫斑病
• 原発性免疫不全症
• 二次免疫不全症

第8章 南北アメリカの血漿タンパク質治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の血漿タンパク質治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの血漿タンパク質治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • GCバイオファーマ、インドネシアの血漿分画工場の起工式
  • プラズマジェン・バイオサイエンス、バンガロールのコラールに最先端の血漿製品製造施設を新設
  • 武田薬品、日本に7億7,000万米ドルの血漿分画療法工場を建設へ

第12章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. PLASMA PROTEIN THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. PLASMA PROTEIN THERAPEUTICS MARKET DYNAMICS
• FIGURE 7. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 12. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 14. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. PLASMA PROTEIN THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 20. PLASMA PROTEIN THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PLASMA PROTEIN THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMINS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMINS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTORS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTORS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULINS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULINS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISORDER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISORDER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 30. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 31. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 32. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 33. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 34. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 35. ARGENTINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 36. ARGENTINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 37. ARGENTINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 38. ARGENTINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 39. BRAZIL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 40. BRAZIL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 41. BRAZIL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 42. BRAZIL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 43. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 44. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 45. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 46. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 47. MEXICO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 48. MEXICO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 49. MEXICO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 50. MEXICO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 51. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 52. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 53. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 54. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 55. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 56. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 58. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 60. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 62. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 63. AUSTRALIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 64. AUSTRALIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 65. AUSTRALIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 66. AUSTRALIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 67. CHINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 68. CHINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 69. CHINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 70. CHINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 71. INDIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 72. INDIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 73. INDIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 74. INDIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 75. INDONESIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 76. INDONESIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 77. INDONESIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 78. INDONESIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 79. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 80. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 81. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 82. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 83. MALAYSIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 84. MALAYSIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 85. MALAYSIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 86. MALAYSIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 87. PHILIPPINES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 88. PHILIPPINES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 89. PHILIPPINES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 90. PHILIPPINES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 91. SINGAPORE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 92. SINGAPORE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 93. SINGAPORE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 94. SINGAPORE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 95. SOUTH KOREA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 96. SOUTH KOREA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 97. SOUTH KOREA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 98. SOUTH KOREA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 99. TAIWAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 100. TAIWAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 101. TAIWAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 102. TAIWAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 103. THAILAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 104. THAILAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 105. THAILAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 106. THAILAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 107. VIETNAM PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 108. VIETNAM PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 109. VIETNAM PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 110. VIETNAM PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 111. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 112. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 113. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 114. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 115. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 116. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 117. DENMARK PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 118. DENMARK PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 119. DENMARK PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 120. DENMARK PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 121. EGYPT PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 122. EGYPT PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 123. EGYPT PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 124. EGYPT PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 125. FINLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 126. FINLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 127. FINLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 128. FINLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 129. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 130. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 131. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 132. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 133. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 134. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 135. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 136. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 137. ISRAEL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 138. ISRAEL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 139. ISRAEL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 140. ISRAEL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 141. ITALY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 142. ITALY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 143. ITALY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 144. ITALY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 145. NETHERLANDS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 146. NETHERLANDS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 147. NETHERLANDS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 148. NETHERLANDS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 149. NIGERIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 150. NIGERIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 151. NIGERIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 152. NIGERIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 153. NORWAY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 154. NORWAY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 155. NORWAY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 156. NORWAY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 157. POLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 158. POLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 159. POLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 160. POLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 161. QATAR PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 162. QATAR PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 163. QATAR PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 164. QATAR PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 165. RUSSIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 166. RUSSIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 167. RUSSIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 168. RUSSIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 169. SAUDI ARABIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 170. SAUDI ARABIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 171. SAUDI ARABIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 172. SAUDI ARABIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 173. SOUTH AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 174. SOUTH AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 175. SOUTH AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 176. SOUTH AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 177. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 178. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 179. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 180. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 181. SWEDEN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 182. SWEDEN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 183. SWEDEN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 184. SWEDEN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 185. SWITZERLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 186. SWITZERLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 187. SWITZERLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 188. SWITZERLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 189. TURKEY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 190. TURKEY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 191. TURKEY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 192. TURKEY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 193. UNITED ARAB EMIRATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 194. UNITED ARAB EMIRATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 195. UNITED ARAB EMIRATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 196. UNITED ARAB EMIRATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 197. UNITED KINGDOM PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 198. UNITED KINGDOM PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 199. UNITED KINGDOM PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 200. UNITED KINGDOM PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 201. PLASMA PROTEIN THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 202. PLASMA PROTEIN THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

[193 Pages Report] The Plasma Protein Therapeutics Market size was estimated at USD 32.55 billion in 2023 and expected to reach USD 36.19 billion in 2024, at a CAGR 11.37% to reach USD 69.18 billion by 2030.

Plasma protein therapeutics consist of medications derived from human plasma, the liquid component of the blood that contains essential proteins responsible for various functions necessary to human health. These therapeutics include an array of highly specialized treatments tailored to address a variety of medical conditions resulting from the absence or malfunctioning of specific plasma proteins. The market for plasma protein therapeutics includes developing, producing, and distributing these proteins for clinical use. Increased prevalence of autoimmune and neurological diseases, along with the increasing need for regular infusions or injections throughout the life of the patient, contribute to the growth of the plasma protein therapeutics market. Surging access and affordability of plasma protein therapies for patients also fuel the market development. The adverse effects of plasma protein therapeutics and strict regulations about handling plasma protein are restricting market growth. Increasing research and development activity related to the plasma protein presents a potential opportunity for growth in the plasma protein therapeutics market. The development of an efficient protein plasma extraction/manufacturing process is expected to create growth in the market.

Product: Rising usage of C1-esterase inhibitors to control and prevent the swelling attacks associated with HAE

Albumin, a protein synthesized by the liver, is responsible for maintaining oncotic blood pressure and transporting hormones, enzymes, and drugs. In therapeutics, albumins are often used as volume expanders in cases of shock or burns and to treat hypoalbuminemia due to liver failure, nephrotic syndrome, or gastrointestinal protein loss. C1-esterase inhibitors are proteins that regulate the complement system, which is part of the body's immune response. They are primarily used to treat hereditary angioedema (HAE), a rare genetic condition that causes swelling in various parts of the body. Coagulation factors are essential proteins in the blood clotting process. Therapeutic coagulation factors prevent and control bleeding in individuals with hemophilia A and B, which are genetic disorders that impair blood clotting. Treatments involve replacing defective or missing clotting factors, which can be administered prophylactically to prevent bleeding episodes or on-demand to manage acute bleeding. Hyperimmune globulins are plasma-derived immunoglobulins with high concentrations of antibodies targeting specific pathogens or toxins. They are used to prevent or treat diseases such as hepatitis B, rabies, tetanus, and certain types of infections in immunocompromised patients. Immunoglobulins (Ig), also known as antibodies, are used in treating a wide array of autoimmune and inflammatory diseases, primary and secondary immunodeficiencies, and certain infections. Intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg) are the two main forms offered, with the choice largely depending on patient preference, tolerability, and vein accessibility. Specific clinical needs lead to the choice among plasma protein products. Albumins and coagulation factors provide critical volume and clotting functions, respectively, often with high-urgency use cases like trauma and surgery and bleeding control for the latter. C1-esterase inhibitors and hyperimmune globulins offer more targeted interventions, focusing on genetic and infectious diseases. Immunoglobulins have the broadest application range, treating various autoimmune and immunodeficiency-related conditions. The manufacturing landscape is dominated by a few key players who robustly respond to medical needs, emphasized by recent advancements such as gene therapies and expanded indications for existing treatments.

Application: Growing application of plasma protein therapeutics in the secondary immunodeficiency due to prevalence of cancer and autoimmune diseases

Hereditary angioedema is a rare genetic disorder indicated by sudden, severe, and unpredictable swelling in various parts of the body. Treatment for HAE involves C1 esterase inhibitor (C1-INH) concentrates and, more recently, recombinant C1-INH therapies and kallikrein inhibitors as on-demand treatment and prevention. The need for these therapies is high, given the life-threatening nature of HAE attacks. Idiopathic thrombocytopenic purpura is an autoimmune disease that results in a low platelet count, leading to easy bruising and bleeding. Intravenous immunoglobulin (IVIG) is generally used to treat ITP, as it can quickly elevate platelet counts. Primary Immunodeficiency Disorders (PID) represent a group of over 300 disorders where part of the body's immune system is missing or functions improperly. Patients typically require lifelong therapy, often with immunoglobulin (Ig) replacement. Secondary Immunodeficiency (SID) arises when an external source such as infection, chemotherapy, or another disease impairs the immune system. The therapeutic needs across these four application segments vary significantly, with demand being shaped by both the acuteness and the chronic nature of each condition. While HAE and ITP typically require rapid response treatments, PID and SID require longer-term management strategies.

Regional Insights

The plasma protein therapeutics market in the Americas is highly developing, with the United States being one of the major global markets, driven by advanced healthcare infrastructure, high patient awareness levels, and the presence of key industry players. The regulatory environment fostered by the FDA ensures stringent quality and safety standards. In South America, Brazil and Argentina are emerging as key markets for plasma protein therapeutics due to growing healthcare expenditures and awareness about plasma-derived therapies. The Asia-Pacific (APAC) region presents a growth opportunity for the plasma protein therapeutics market, attributed to rising healthcare awareness, increasing disposable incomes, and a growing aging population. China and Japan are significant markets in this region, with China investing heavily in plasma collection and fractionation capabilities. Europe has well-established healthcare systems, high-quality standards, and favorable reimbursement policies. The need for immunoglobulins remains robust, and European countries are significant exporters of plasma products. The Gulf Cooperation Council (GCC) countries demonstrate a rising need for plasma protein therapeutics due to economic prosperity and increased healthcare spending. Conversely, Africa faces considerable hurdles in healthcare infrastructure and treatment access, although the interest in plasma-derived medicinal products is growing.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Plasma Protein Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Plasma Protein Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Plasma Protein Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Access Biologicals LLC, ADMA Biologics, Inc., AmerisourceBergen Corporation, Baxter International Inc., Bio Products Laboratory Ltd., Bruker Corporation, China Biologic Products Holdings, Inc., CSL Limited, DiaPharma, Emergent BioSolutions, FFF Enterprises, Inc., GC Biopharma corp, Grifols, S.A., Hemarus Therapeutics Limited, KalVista Pharmaceuticals, Kamada Ltd., Kedrion S.p.A., Laboratory Corporation of America Holdings, LFB SA, Octapharma AG, Plasma Technologies, LLC, PlasmaGen BioSciences Pvt. Ltd., Reliance Industries Limited, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Plasma Protein Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Product
  • Albumins
  • C1-esterase Inhibitors
  • Coagulation Factors
  • Hyperimmune Globulins
  • Immunoglobulins

• Application
  • Hereditary Angioedema
  • Idiopathic Thrombocytopenic Purpura
  • Primary Immunodeficiency Disorder
  • Secondary Immunodeficiency

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Plasma Protein Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Plasma Protein Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Plasma Protein Therapeutics Market?

4. What is the market share of the leading vendors in the Plasma Protein Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Plasma Protein Therapeutics Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increased Prevalence of Autoimmune and Neurological Diseases
    • 5.1.1.2. Need for Regular Infusions or Injections Throughout the Life of the Patient
    • 5.1.1.3. Surging Access and Affordability of Plasma Protein Therapies for Patients
  • 5.1.2. Restraints
    • 5.1.2.1. Adverse Effects of Plasma Protein Therapeutics
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing Research and Development Activity Related to the Plasma Protein
    • 5.1.3.2. Development of Efficient Protein Plasma Extraction/Manufacturing Process
  • 5.1.4. Challenges
    • 5.1.4.1. Strict Regulations Pertaining to Handling of Plasma Protein
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Rising usage of C1-esterase inhibitors to control and prevent the swelling attacks associated with HAE
  • 5.2.2. Application: Growing application of plasma protein therapeutics in the secondary immunodeficiency due to prevalence of cancer and autoimmune diseases
• 5.3. Market Trend Analysis
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework Analysis
• 5.9. Client Customization

6. Plasma Protein Therapeutics Market, by Product

• 6.1. Introduction
• 6.2. Albumins
• 6.3. C1-esterase Inhibitors
• 6.4. Coagulation Factors
• 6.5. Hyperimmune Globulins
• 6.6. Immunoglobulins

7. Plasma Protein Therapeutics Market, by Application

• 7.1. Introduction
• 7.2. Hereditary Angioedema
• 7.3. Idiopathic Thrombocytopenic Purpura
• 7.4. Primary Immunodeficiency Disorder
• 7.5. Secondary Immunodeficiency

8. Americas Plasma Protein Therapeutics Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Plasma Protein Therapeutics Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Plasma Protein Therapeutics Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
  • 11.3.1. GC Biopharma's groundbreaking for the plasma fractionation plant in Indonesia
  • 11.3.2. PlasmaGen Biosciences Opens New, State-of-the-Art Manufacturing Facility for Blood Plasma Products in Kolar, Bengaluru
  • 11.3.3. Takeda to build USD 770 million plasma-derived therapy plant in Japan

12. Competitive Portfolio

• 12.1. Key Company Profiles
• 12.2. Key Product Portfolio